血友病治療薬の世界市場2016-2020

◆英語タイトル:Global Hemophilia Drugs Market 2016-2020
◆商品コード:IRTNTR10470
◆発行会社(調査会社):Technavio
◆発行日:2016年10月19日
◆ページ数:84
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、血友病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、血友病治療薬の世界市場規模及び予測、種類別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Hemophilia
Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.

Technavio’s analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Baxalta
• Bayer
• CSL Behring
• Novo Nordisk
• Pfizer

[Other prominent vendors]
• Alnylam Pharmaceuticals
• Amarna Therapeutics
• Asklepios BioPharmaceutical
• Biogen
• BioMarin
• Catalyst Bioscience
• Chiesi Farmaceutici
• Dimension Therapeutics
• Emergent BioSolutions
• F. Hoffmann-La Roche
• Grifols, Kedrion Biopharma
• Octapharma
• rEVO Biologics
• OPKO Biologics
• Sangamo Biosciences
• Spark Therapeutics
• Swedish Orphan Biovitrum
• UniQure Biopharma.

[Market driver]
• Focus on prophylactic treatment
• For a full, detailed list, view our report

[Market challenge]
• Low diagnosis rate
• For a full, detailed list, view our report

[Market trend]
• Increase in technological innovations
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by type of disease
• Global hemophilia A drugs market
• Global hemophilia inhibitors treatment market
• Global hemophilia B drugs market
• Global von Willebrand disease treatment market

PART 08: Market segmentation by type of therapy
• Recombinant therapies
• Plasma-derived therapies

PART 09: Market segmentation by type of disease management
• Prophylaxis
• On-demand therapy
• Inhibitor therapy

PART 10: Geographical segmentation
• Hemophilia drugs market in Americas
• Hemophilia drugs market in EMEA
• Hemophilia drugs market in APAC

PART 11: Market drivers
• Focus on prophylactic treatment
• Drugs with prolonged action
• Improved diagnostic procedures

PART 12: Impact of drivers

PART 13: Market challenges
• Low diagnosis rate
• High entry barriers
• Cost-intensive complex treatment

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Increase in technological innovations
• Development of gene therapy products
• Centralized buyers should pave the way to increased penetration

PART 16: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 17: Key vendor analysis
• Baxalta
• Bayer
• CSL Behring
• Novo Nordisk
• Pfizer

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Process of gene therapy
Exhibit 03: Key buying criteria for global hemophilia drugs market 2015
Exhibit 04: Key customer segments of hemophilia drugs market
Exhibit 05: Pipeline portfolio: Global hemophilia drugs market
Exhibit 06: Pipeline share of major companies
Exhibit 07: Global hemophilia drugs market snapshot: Developed and emerging markets 2015
Exhibit 08: Global hemophilia drugs market 2015-2020 ($ billions)
Exhibit 09: Impact of factors affecting the market 2015 and 2020
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global hemophilia drugs market by disease type based on revenue 2015
Exhibit 12: Global hemophilia drugs market segmentation growth lifecycle analysis
Exhibit 13: Global hemophilia drugs market by disease type 2015-2020
Exhibit 14: Global hemophilia A drugs market 2015-2020 ($ billions)
Exhibit 15: Global hemophilia inhibitors treatment market 2015-2020 ($ billions)
Exhibit 16: Global hemophilia B drugs market 2015-2020 ($ billions)
Exhibit 17: Global von Willebrand disease treatment market 2015-2020 ($ millions)
Exhibit 18: Segmentation of global hemophilia drugs market by type of therapy based on revenue 2015
Exhibit 19: Global hemophilia drugs market by type of therapy 2015-2020
Exhibit 20: Recombinant therapies in global hemophilia drugs market 2015-2020 ($ billions)
Exhibit 21: Plasma-derived therapies in global hemophilia drugs market 2015-2020 ($ billions)
Exhibit 22: Segmentation of hemophilia inhibitors treatment market by type of disease management based on revenue 2015
Exhibit 23: Global hemophilia drugs market by geography 2015-2020
Exhibit 24: Percentage share of global hemophilia drugs market by geography 2015 and 2020
Exhibit 25: Global hemophilia drugs market segmentation by geography 2015-2020 ($ billions)
Exhibit 26: Global share of hemophilia drugs market by geography 2015
Exhibit 27: Global hemophilia drugs market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 28: Global hemophilia drugs market: Country analysis based on revenue and growth rate
Exhibit 29: Opportunity analysis of hemophilia drugs market in Americas
Exhibit 30: Hemophilia drugs market in Americas 2015-2020 ($ billions)
Exhibit 31: Opportunity analysis of hemophilia drugs market in EMEA
Exhibit 32: Hemophilia drugs market in EMEA 2015-2020 ($ billions)
Exhibit 33: Opportunity analysis of hemophilia drugs market in APAC
Exhibit 34: Hemophilia drugs market in APAC 2015-2020 ($ billions)
Exhibit 35: Impact of drivers
Exhibit 36: Percentage share of diagnosed and undiagnosed hemophilia population 2012-2016
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Gene therapies under development for hemophilia
Exhibit 39: Market share of vendors 2015
Exhibit 40: Geographical presence of key vendors
Exhibit 41: Competitive scenario of global hemophilia drugs market vendors 2015-2020
Exhibit 42: Baxalta: Strength assessment
Exhibit 43: Baxalta: Strategy assessment
Exhibit 44: Baxalta: Opportunity assessment
Exhibit 45: Baxalta: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
Exhibit 46: Bayer: Strength assessment
Exhibit 47: Bayer: Strategy assessment
Exhibit 48: Bayer: Opportunity assessment
Exhibit 49: Bayer: YoY revenue and growth rate of Kogenate FS 2013-2015 ($ billions)
Exhibit 50: CSL Behring: Strength assessment
Exhibit 51: CSL Behring strategy assessment
Exhibit 52: CSL Behring opportunity assessment
Exhibit 53: CSL Behring: YoY revenue and growth rate of hemophilia drugs 2013-2015 ($ billions)
Exhibit 54: Novo Nordisk: Strength assessment
Exhibit 55: Novo Nordisk: Strategy assessment
Exhibit 56: Novo Nordisk: Opportunity assessment
Exhibit 57: Novo Nordisk: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
Exhibit 58: Pfizer: Strength assessment
Exhibit 59: Pfizer: Strategy assessment
Exhibit 60: Pfizer: Opportunity assessment
Exhibit 61: Pfizer: Revenue of ReFacto AF/XYNTHA and BeneFIX 2015 ($ millions)



【掲載企業】

Baxalta, Bayer, CSL Behring, Novo Nordisk, Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen, BioMarin, Catalyst Biosciences, Chiesi Farmaceutici, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Grifols, Kedrion Biopharma, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum, UniQure Biopharma.

【レポートのキーワード】

血友病治療薬、血友病A薬、血友病B薬、医療、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[血友病治療薬の世界市場2016-2020] (コード:IRTNTR10470)販売に関する免責事項を必ずご確認ください。
★調査レポート[血友病治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆